Approach to optic neuritis: An update

15Citations
Citations of this article
113Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Over the past few years, there has been remarkable development in the area of optic neuritis. The discovery of new antibodies has improved our understanding of the pathology of the disease. Antiaquaporin4 antibodies and antimyelin oligodendrocytes antibodies are now considered as distinct entities of optic neuritis with their specific clinical presentation, neuroimaging characteristics, treatment options, and course of the disease. Similarly, there has been a substantial change in the treatment of optic neuritis which was earlier limited to steroids and interferons. The development of new immunosuppressant drugs and monoclonal antibodies has reduced the relapses and improved the prognosis of optic neuritis as well as an associated systemic disease. This review article tends to provide an update on the approach and management of optic neuritis.

Cite

CITATION STYLE

APA

Phuljhele, S., Kedar, S., & Saxena, R. (2021, September 1). Approach to optic neuritis: An update. Indian Journal of Ophthalmology. Wolters Kluwer Medknow Publications. https://doi.org/10.4103/ijo.IJO_3415_20

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free